Cettire Limited

CTT

Cettire Ltd. is an online luxury goods retailer, which engages in luxury personal items such as clothing, shoes, bags, and accessories via their website. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-12-18. The firm is engaged in offering a selection of in demand personal luxury goods via its Website, cettire.com. The company has access to an extensive catalogue of more than 2,500 luxury brands and 500,000 products of clothing, shoes, bags, and accessories. The company sells a range of products from over 500 designers, which include a range of women's and men's wear from brands, such as Prada, Gucci, Saint Laurent, Balenciaga, and Valentino, among others. The firm's product categories include clothing, shoes, bags, and accessories. Its clothing category offers activewear, coats, jackets, jeans, knitwear, pants, and various others. Its shoes category offers boots, espadrilles, lace-up shoes, loafers, and various others. The Company’s bags category offers bag accessories, belt bags, clutch bags, crossbody bags and various others. The firm also offers accessories, such as belts, glasses, gloves, hats, and various others.

Clarity Pharmaceuticals Ltd

CU6

Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. The company is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. The company has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.

Central Petroleum Limited

CTP

Central Petroleum Ltd. engages in the provision of development, production, processing and marketing of hydrocarbons and associated exploration. The company is headquartered in Brisbane, Queensland and currently employs 80 full-time employees. The company went IPO on 2006-03-07. The firm is focused on supplying reliable energy to Australians. Its diverse portfolio of producing and prospective gas tenements across the Northern Territory (NT) and Queensland. Its central portfolio encompasses opportunities within the Amadeus, Southern Georgina, Wiso, and Surat Basins. The Amadeus Basin has, to date, been a focus for most of the Company's exploration activity, approximately 170,000 square kilometers of areal extent, five known working petroleum gas systems, and four fields having produced significant quantities of oil and gas.